Ignite Creation Date:
2024-05-06 @ 8:20 PM
Last Modification Date:
2024-10-26 @ 3:25 PM
Study NCT ID:
NCT06346912
Status:
RECRUITING
Last Update Posted:
2024-05-14
First Post:
2024-03-29
Brief Title:
CD19-BAFF CAR-T Cells Therapy for Patients With Relapsed Refractory B-cell ALL and B-cell NHL
Sponsor:
Zhejiang University
Organization:
Zhejiang University
Study Overview
Official Title:
A Study of CD19-BAFF CAR-T Cells Therapy for Patients With Relapsed andor Refractory B-cell ALL and B-cell NHL
Status:
RECRUITING
Status Verified Date:
2023-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Clinical Trial for the safety and efficacy of CD19-BAFF CAR-T cells therapy for refractoryrelapsed B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma
Detailed Description:
In this study 20 patients with relapsed refractory B-cell ALL and B-cell NHL were proposed to undergo CD19-BAFF CAR-T cell therapy Under the premise that its safety has been clarified in previous studies further observation and evaluation of the effectiveness of CD19-BAFF CAR-T cell therapy for relapsed refractory B-cell ALL and B-cell NHL At the same time on the basis of expanding the sample size more safety data on CD19-BAFF CAR-T cell treatment for relapsed refractory B-cell ALL and B-cell NHL were accumulated including rare and delayed complications
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None